Eugia Pharma Receives USFDA Approval for Arsenic Trioxide Injection 12 mg/6 mL
Published: October 15, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Arsenic Trioxide Injection 12 mg/6 mL.
Indications for this product include:
- Induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.
Refer to package insert for full prescribing information.